(以下内容从万联证券《医药生物行业快评报告:三生制药双抗授权辉瑞,有望成为中国生物药License-out新标杆》研报附件原文摘录)事件:5月20日,三生制药宣布该公司及附属子公司沈阳三生、三生国健与辉瑞(Pfizer)签署协议,将向辉瑞独家授予PD-1/VEGF双特异性抗体SSGJ-707在全球(不包括中国内地)的开发、生产、商业化权利。三生制药及沈阳三生将保留SSGJ-707在中国内地的开发、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.